Arcus Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 577
- Market Cap
- -
- Website
- http://www.arcusbio.com
- Introduction
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05154136
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05117554
- Locations
- 🇳🇱
Investigational Site, Groningen, Netherlands
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT04772989
- Locations
- 🇺🇸
University of Wisconsin - Madison, Madison, Wisconsin, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT04736173
- Locations
- 🇺🇸
City of Hope-Duarte, Duarte, California, United States
🇺🇸City of Hope - Huntington Beach (Including Long Beach Elm), Huntington Beach, California, United States
🇺🇸City Of Hope, Irvine, California, United States
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 227
- Registration Number
- NCT04660812
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Careggi-S.O.D. Patologia Medica, Firenze, Italy
🇮🇹Azienda Ospedaliera Niguarda Ca' Granda, Milano, Italy
🇮🇹Instituto Europeo di Oncologia, Milano, Italy
A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04575311
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 173
- Registration Number
- NCT04381832
- Locations
- 🇺🇸
Florida Cancer Specialists East, West Palm Beach, Florida, United States
🇺🇸The Oncology Institute of Hope & Innovation, Cerritos, California, United States
🇺🇸The University of California, Los Angeles, Encino, California, United States
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT04262856
- Locations
- 🇺🇸
Allegheny General Hospital (AGH)-Alleghney Singer Research Institute, Pittsburgh, Pennsylvania, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Innovative Clinical Research Institute (ICRI), Whittier, California, United States
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT04104672
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸UW Health - UW Carbone Cancer Center - Medical Oncology Clinic, Madison, Wisconsin, United States
Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04087018
- Locations
- 🇺🇸
Saint Francis Cancer Center, Greenville, South Carolina, United States
🇺🇸Christiana Care Health System - Helen F. Graham Cancer Center, Newark, Delaware, United States
🇺🇸Prisma Health, Greenville, South Carolina, United States